2013
Vandetanib for aggressive and symptomatic medullary thyroid cancer
Deshpande H, Carling T, Khan N, Holt E. Vandetanib for aggressive and symptomatic medullary thyroid cancer. Journal Of Clinical Practice 2013, 10: 275-282. DOI: 10.2217/cpr.13.17.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerSymptomatic medullary thyroid cancerMetastatic medullary thyroid cancerNew tyrosine kinase inhibitorsThyroid cancer accountsTyrosine kinase inhibitorsAggressive metastatic formsGrowth factor receptorProto-oncogene RETCancer accountsClinical trialsSignificant symptomsMetastatic formSporadic formsMalignant cellsUS FDAClinical useVandetanibKinase inhibitorsFactor receptorCancerFirst agentPhase IIDisease
2012
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Deshpande H, Sheth K, Sosa J, Roman S. Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer. Clinical Medicine Insights Oncology 2012, 6: cmo.s8305. PMID: 23133319, PMCID: PMC3489097, DOI: 10.4137/cmo.s8305.Peer-Reviewed Original ResearchMedullary thyroid carcinomaProgressive medullary thyroid carcinomaAdvanced medullary thyroid carcinomaManagement of MTCMedullary thyroid cancerAdvanced diseasePharmacotherapy optionsConventional chemotherapyThyroid cancerThyroid carcinomaNovel treatmentsUS FoodDrug AdministrationTreatmentTherapyDiseaseEfficacyTolerabilityChemotherapyPatientsCarcinomaVandetanibCancerAdministration